Premium
O1‐11‐03: Prevalence of Amyloid‐b Pathology in Primary Progressive Aphasia Variants: A Multicenter Study
Author(s) -
Bergeron David,
Laforce Robert,
Visser Pieter Jelle,
Ossenkoppele Rik
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.354
Subject(s) - primary progressive aphasia , medicine , frontotemporal dementia , pathology , neuropathology , amyloid (mycology) , oncology , frontotemporal lobar degeneration , dementia , disease
Gottingen (n1⁄440). CSF H-FABP, Ab42, t-tau and p-tau levels were measured with ELISA immunoassays. Results:CSF H-FABP levels were significantly higher in AD and DLB patients compared to PD and controls; a similar trend was observed in the PDD group .CSF ttau levels were significantly increased in AD as compared to PDD, DLB, PD and controls. CSF H-FABP significantly correlated with CSF t-tau levels (r1⁄40.64, p<0.001). CSF H-FABP/t-tau ratio showed a high accuracy for differential diagnosis between AD and DLB (AUC1⁄40.92, specificity 83%, sensitivity 88%) and between AD and PDD (AUC1⁄40.97, specificity 89%, sensitivity 95%). H-FABP showed an inverse correlation with cognitive decline, as assessed with Mini Mental Status Examination (r 1⁄4 -0.41, p<0.001). Conclusions: CSF H-FABP can be considered a neurodegeneration biomarker possibly linked to the development of dementia. The combination of H-FABP with the core AD CSF biomarkers may help to improve the differential diagnosis of dementia disorders. [1] Chiasserini, D. et al., J. Alzheimers. Dis. 2010;22(4):1281-8. [2] Mollenhauer, B. et al., 2007, 02115, 366– 375. [3] Backstrom DC et al., Jama Neur.2015 Oct; 72 (10): 1175-82.